


=> d 11
 L1 HAS NO ANSWERS
 L1 STR



G1 H, X, Ak, NO2

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 06:51:32 ON 25 JUN 2003)

FILE 'REGISTRY' ENTERED AT 06:51:40 ON 25 JUN 2003



L1 STRUCTURE uploaded
 L2 7 S L1
 L3 84 S L1 FULL
 L4 84 S L3 AND CAPLUS/LC
 L5 0 S L3 AND CAOLD/LC

FILE 'CAPLUS' ENTERED AT 06:52:56 ON 25 JUN 2003

L6 3 S L3

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:34889 CAPLUS
 DOCUMENT NUMBER: 130:95549
 TITLE: Preparation of N-sulfonyl(benzylamino)benzamide,
 N-sulfonylbenzylimidazolepropanamide, and
 N-sulfonylpyridinecarboxamide having hypoglycemic and
 phosphodiesterase 5 (PDE 5) inhibitory activities
 INVENTOR(S): Yamasaki, Noritsugu; Imoto, Takafumi; Hiramura,
 Takahiro; Onomura, Osamu; Nishikawa, Masahiro;
 Kayakiri, Hiroshi; Abe, Yoshito; Hamashima, Hitoshi;
 Sawada, Hitoshi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900359	A1	19990107	WO 1998-JP2886	19980626
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1000932	A1	20000517	EP 1998-929724	19980626
R: CH, DE, ES, FR, GB, IT, LI				
US 6242474	B1	20010605	US 2000-446619	20000321
PRIORITY APPLN. INFO.:			JP 1997-187849	A 19970627
			WO 1998-JP2886	W 19980626
OTHER SOURCE(S):	MARPAT	130:95549		
GI				



AB Novel arom. ring derivs. represented by general formula [I; R2 = (un)substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclyl; ch1, ch2 = (un)branched satd. or unsatd. bridging group wherein ch1 is optionally substituted by lower alkyl, lower cycloalkyl,

aryl, heterocyclyl, lower alkyl-lower cycloalkyl, aryl-lower alkyl, or heterocyclyl-lower alkyl; Nu = 5- or 6-membered ring; X and Nu may be directly linked to each other; R1 = H, halo, lower alkyl, NH₂, acylamino, lower alkyl alkenyl, alkynyl, halo-lower alkyl, lower cycloalkyl, NO₂, lower alkyl-amino, CO₂H or its ester, amidated CO₂H, lower alkanesulfonyl, arylsulfonyl, OH, lower alkoxy; n = integer of .1toreq.2; A = (un)substituted aryl] or pharmaceutically acceptable salts thereof are prepd. Because of having hypoglycemic and PDE 5 inhibitory activities, these compds. and salts thereof are useful as remedies for impaired glucose tolerance, diabetes, complication of diabetes, insulin-resistant syndrome, polycystic ovary syndrome, hyperlipidemia, atherosclerosis, cardiovascular diseases, hyperglycemia, hypertension, angina pectoris, pulmonary hypertension, congestive heart failure, glomerular diseases, tubular interstitial diseases, renal insufficiency, atherosclerosis, angiostenosis, peripheral vascular diseases, cerebral stroke, chronic reversible obstructive diseases, autoimmune diseases, allergic rhinitis, urticaria, glaucoma, diseases characterized by disordered intestinal motion, sexual impotence, nephritis, cachexia, pancreatitis, post-(percutaneous transluminal coronary angioplasty) PTCA recontriction, etc. Thus, (E)-3-(4-bromo-1-(2,4-dichlorobenzyl)-2-methylimidazol-5-yl)-2-propenoic acid was stirred with N,N'-carbonyl diimidazole in DMF at room temp. for 1 h and then condensed with pentanesulfonamide in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene at 100.degree. for 3 h to give the title compd. (II). Another compd., 4-(acetamido)-3-(N-methyl-2,4-dichlorobenzylamino)-[N-(n-pentanesulfonyl)]benzamide (III) (prepn. given), lowered glucose and triglyceride level by 60 and 104%, resp., when a feed contg. 0.01% III was fed to mice twice per wk for 14 days.

IT 219503-80-7P 219503-84-1P 219503-86-3P

219503-88-5P 219503-90-9P 219504-01-5P

219504-02-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-sulfonyl(benzylamino)benzamide, N-sulfonylbenzylimidazolepropanamide, and N-sulfonylpyridinecarboxamide having hypoglycemic and phosphodiesterase 5 inhibitory activities as drugs)


RN 219503-80-7 CAPLUS

CN 2-Propenamide, 3-[4-bromo-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 219503-84-1 CAPLUS
 CN 1H-Imidazole-5-propanamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)- (9CI) (CA INDEX NAME)




RN 219503-86-3 CAPLUS
 CN 2-Propenamide, 3-[(1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl)-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 219503-88-5 CAPLUS
 CN 2-Propenamide, 3-[(4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl)-N-(pentylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219503-90-9 CAPLUS

CN 2-Propenamide, 3-[4-chloro-1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]-N-(phenylsulfonyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219504-01-5 CAPLUS

CN 2-Thiophene propanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 219504-02-6 CAPLUS

CN Benzenepropanamide, .alpha.-[[1-[(2,4-dichlorophenyl)methyl]-2-methyl-1H-imidazol-5-yl]methylene]-N-(pentylsulfonyl)-, (.alpha.E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT